Yueshan Li

Cancer Center And State Key Laboratory Of Biotherapy
Chengdu, 610041, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Small-molecule inhibition of YTHDC1 as a strategy against acute myeloid leukemia in mouse models.

Small-molecule inhibition of YTHDC1 as a strategy against acute myeloid leukemia in mouse models.

Journal: Science translational medicine

Published: February 04, 2026

Discovery of Deuterated 3,4-Dihydro-benzo[e][1,4]diazepine-2,5-dione Derivatives as Potent, Selective and Orally Bioavailable ROCK2 Inhibitors.

Discovery of Deuterated 3,4-Dihydro-benzo[e][1,4]diazepine-2,5-dione Derivatives as Potent, Selective and Orally Bioavailable ROCK2 Inhibitors.

Journal: Journal of medicinal chemistry

Published: November 25, 2025

YL1004 is a SARS-CoV-2 papain-like protease inhibitor with immunomodulatory and antiviral activity in mice.

YL1004 is a SARS-CoV-2 papain-like protease inhibitor with immunomodulatory and antiviral activity in mice.

Journal: Nature communications

Published: September 01, 2025

Structure-based identification of a G protein-biased allosteric modulator of cannabinoid receptor CB1.

Structure-based identification of a G protein-biased allosteric modulator of cannabinoid receptor CB1.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: June 03, 2024

From Hit to Lead: Structure-Based Optimization of Novel Selective Inhibitors of Receptor-Interacting Protein Kinase 1 (RIPK1) for the Treatment of Inflammatory Diseases.

From Hit to Lead: Structure-Based Optimization of Novel Selective Inhibitors of Receptor-Interacting Protein Kinase 1 (RIPK1) for the Treatment of Inflammatory Diseases.

Journal: Journal of medicinal chemistry

Published: December 30, 2023

Discovery of benzodiazepine derivatives as a new class of covalent inhibitors of SARS-CoV-2 main protease.

Discovery of benzodiazepine derivatives as a new class of covalent inhibitors of SARS-CoV-2 main protease.

Journal: Bioorganic & medicinal chemistry letters

Published: June 05, 2023

Discovery and structure-activity relationship studies of novel α-ketoamide derivatives targeting the SARS-CoV-2 main protease.

Discovery and structure-activity relationship studies of novel α-ketoamide derivatives targeting the SARS-CoV-2 main protease.

Journal: European journal of medicinal chemistry

Published: May 30, 2023

Generative deep learning enables the discovery of a potent and selective RIPK1 inhibitor.

Generative deep learning enables the discovery of a potent and selective RIPK1 inhibitor.

Journal: Nature communications

Published: April 12, 2022

Discovery of 3,4-Dihydrobenzo[f][1,4]oxazepin-5(2H)-one Derivatives as a New Class of Selective TNIK Inhibitors and Evaluation of Their Anti-Colorectal Cancer Effects.

Discovery of 3,4-Dihydrobenzo[f][1,4]oxazepin-5(2H)-one Derivatives as a New Class of Selective TNIK Inhibitors and Evaluation of Their Anti-Colorectal Cancer Effects.

Journal: Journal of medicinal chemistry

Published: January 05, 2022

RIPK1 inhibition enhances the therapeutic efficacy of chidamide in FLT3-ITD positive AML, both in vitro and in vivo.

RIPK1 inhibition enhances the therapeutic efficacy of chidamide in FLT3-ITD positive AML, both in vitro and in vivo.

Journal: Leukemia & lymphoma

Published: December 06, 2021

Fe3+-citric acid/sodium alginate hydrogel: A photo-responsive platform for rapid water purification.

Fe3+-citric acid/sodium alginate hydrogel: A photo-responsive platform for rapid water purification.

Journal: Carbohydrate polymers

Published: March 04, 2021

Discovery of 3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one derivatives as a new class of ROCK inhibitors for the treatment of glaucoma.

Discovery of 3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one derivatives as a new class of ROCK inhibitors for the treatment of glaucoma.

Journal: Bioorganic & medicinal chemistry letters

Published: February 05, 2021

Showing 1-12 of 16

Last Updated: 09/26/2026